Scientists Innovate Non-Hallucinogenic Psychedelic Compound with Potential for Schizophrenia Treatment
In a significant breakthrough in neuropsychiatric medicine, a team of researchers from the University of California, Davis and San Diego has created a new compound inspired by psychedelics, which could change treatment approaches for disorders such as schizophrenia. Named JRT, this cutting-edge molecule replicates various neurological advantages of LSD—one of the most thoroughly researched psychedelics—without triggering the hallucinations often associated with these substances.
A Minor Adjustment, a Significant Breakthrough
The research, recently featured in the Proceedings of the National Academy of Sciences, outlines how the team successfully modified LSD’s molecular framework by merely repositioning two atoms. This seemingly minor alteration yielded substantial results: it maintained the compound’s capability to enhance neural plasticity while significantly diminishing its likelihood of causing hallucinogenic side effects.
“We basically performed a simple tire rotation,” explained Dr. David E. Olson, the lead author of the study and director of the Institute for Psychedelics and Neurotherapeutics at UC Davis. “By transposing just two atoms in LSD, we greatly refined JRT’s selectivity profile and lowered its hallucinogenic potential.”
A New Era of Medicine: Psychoplastogens
JRT is classified under a new category of compounds called psychoplastogens—molecules that foster neural plasticity, which is the brain’s capacity to develop and reorganize. Utilizing advanced 3D electron microscopy, the researchers revealed that a single administration of JRT resulted in a 46% rise in dendritic spine density in the prefrontal cortex of mice while increasing synapse density by 18%. Dendritic spines play a crucial role in facilitating communication between nerve cells and are frequently diminished in individuals experiencing mental health disorders, including schizophrenia.
Moreover, the compound exhibited the capability to reinstate cognitive flexibility—a vital mental process that is often impaired in schizophrenia and other mental health issues—in mice exposed to prolonged stress. Unlike many current psychotropic medications, JRT did not cause sedation or other unwanted effects, making it a notably promising option for therapeutic applications.
Importance for Schizophrenia Management
Existing antipsychotic treatments predominantly focus on alleviating symptoms such as hallucinations and delusions, but often fall short in addressing deeper concerns like cognitive deficits or emotional numbing (anhedonia). These cognitive and negative symptoms can be profoundly debilitating and resistant to available pharmacological treatments.
“Patients with schizophrenia don’t generally want to be given a hallucinogenic substance like LSD,” remarked Olson, who is also a co-founder of Delix Therapeutics, a startup dedicated to psychoplastogenic compounds. “The creation of JRT highlights the potential to utilize psychedelics such as LSD as foundational elements to develop improved medications—ones that can be applicable to patient groups where psychedelic use is not an option.”
In comparison to ketamine—a rapid-acting antidepressant recognized for enhancing plasticity—JRT is projected to be approximately 100 times more effective in yielding antidepressant-like outcomes in preclinical assessments. This strength, alongside the absence of hallucinogenic effects, positions JRT as a frontrunner in the advancement of next-generation psychoplastogenic therapies.
Initiating a Biopharmaceutical Revolution
The journey to this discovery was not straightforward. It required almost five years for the research team to formulate the 12-step chemical synthesis essential for producing JRT. The compound is named in tribute to Jeremy R. Tuck, the graduate student who first synthesized it in the laboratory.
“This research exemplifies how innovative chemistry, neuroscience, and imaging can converge to advance the frontiers of biomedical exploration,” stated Uri Manor, co-author of the study and assistant professor at UC San Diego’s School of Biological Sciences.
Advancing the Future of Mental Health Investigation
The potential applications of JRT extend well beyond schizophrenia. Researchers are now exploring the molecule’s capacity to address other neurodegenerative and psychiatric disorders, such as depression, PTSD, and possibly even Alzheimer’s disease. By aiming to repair or enhance neural function, compounds like JRT could significantly alter future treatments for mental health and brain disorders.
This groundbreaking work received support from various organizations, including the National Institutes of Health, the UC Davis Provost’s Undergraduate Fellowship, the Camille and Henry Dreyfus Foundation, and the Chan Zuckerberg Initiative.
As research continues to uncover the intricacies of the brain, innovations like JRT underscore the vital role of advancement at the crossroads of chemistry, neuroscience, and empathetic care. By imitating the therapeutic effects of psychedelic substances while mitigating their risks, researchers are potentially paving a new route toward safer and more effective solutions for individuals facing some of the most formidable challenges of the mind.
Support Knowledge-Driven Science
If this narrative has educated or motivated you, please consider making a contribution to support independent scientific journalism. It takes resources and commitment to ensure essential stories like this reach the audience. Every donation, no matter its size, aids in maintaining